Eli Lilly Surges 4.6% as Novo Nordisk Trial Misses on Weight-Loss Efficacy
Eli Lilly shares climbed 4.59% as investors reallocated from Novo Nordisk, whose REDEFINE 4 trial failed to match tirzepatide’s 23.6% weight loss, showing only 20.2% with CagriSema in 809 subjects over 84 weeks. Novo Nordisk stock hit a 52-week low, boosting broader healthcare sector momentum.
1. REDEFINE 4 Trial Results
The REDEFINE 4 Phase 3 trial enrolled 809 subjects over 84 weeks and tested Novo Nordisk’s CagriSema against Eli Lilly’s tirzepatide. CagriSema achieved 20.2% mean weight loss versus 23.6% with tirzepatide, failing to demonstrate non-inferiority and triggering a 52-week low in Novo Nordisk’s share price.
2. Eli Lilly Stock Reaction
Eli Lilly’s stock surged 4.59% as investors shifted positions following the trial setback. Technical indicators show mixed momentum, with shares trading below the 20-day and 100-day simple moving averages but supported by a neutral RSI reading.
3. Sector Impact and Outlook
The S&P 500 edged up 0.04% and the Healthcare sector rose 0.58%, reflecting positive sentiment around obesity treatment leaders. Market participants will watch upcoming trial readouts and competitive pipeline updates for further catalysts.